Sermorelin, Ipamorelin & CJC-1295: Research Overview

For laboratory and research use only. The following content is provided for scientific and educational purposes. Olympia Peptides compounds are not intended for human consumption, injection, or clinical use and have not been evaluated by the Food and Drug Administration. This content does not constitute medical advice. See our full disclaimer.

Growth hormone secretagogue (GHS) peptides represent one of the more actively studied peptide classes in preclinical endocrinology research. Sermorelin, ipamorelin, and CJC-1295 each interact with distinct receptor targets along the hypothalamic-pituitary axis, making them subjects of ongoing investigation in animal models and in vitro systems. Researchers studying GH/IGF-1 signaling pathways have used these peptides to probe the regulatory dynamics of growth hormone release, downstream anabolic signaling, and the physiological consequences of altered secretagogue activity. This post provides a research-oriented overview of each compound’s molecular profile, published study context, and proposed mechanisms.

What Is Sermorelin Peptide?

Sermorelin (GHRH 1–29 NH₂) is a synthetic analogue of endogenous growth hormone-releasing hormone (GHRH), comprising the first 29 amino acids of the native 44-residue peptide. It retains full biological activity at the GHRH receptor (GHRHR), a G protein-coupled receptor expressed on anterior pituitary somatotroph cells. Upon binding, sermorelin is proposed to activate adenylyl cyclase via Gs signaling, elevating intracellular cAMP and stimulating GH secretion in a physiologically pulsatile pattern. Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) classified as a GH secretagogue receptor (GHS-R1a) agonist — a distinct receptor class from GHRHR. CJC-1295 is a long-acting GHRH analogue modified with a Drug Affinity Complex (DAC) moiety that enables covalent binding to serum albumin, dramatically extending plasma half-life in animal studies compared to native GHRH or sermorelin.

Published Research Landscape

Sermorelin in Preclinical Studies

Sermorelin has been studied extensively in animal models since the 1980s. Research published in Endocrinology and Journal of Clinical Endocrinology & Metabolism characterized its receptor binding kinetics and dose-response relationships for GH secretion in rat pituitary cell preparations. Walker and colleagues demonstrated in ovine models that GHRH 1–29 fragments retained full somatotroph stimulatory activity, establishing the truncated analogue as a valid research tool. Studies in aged rat models have investigated whether GHRH receptor sensitivity changes across the lifespan, with sermorelin used as the probe ligand.

Ipamorelin Research

Ipamorelin was first characterized by Raun et al. (1998) in a study published in the European Journal of Endocrinology, which reported high GHS-R1a selectivity and a favorable GH-stimulating profile in animal models with minimal concurrent ACTH or cortisol elevation — a property that distinguished it from earlier GHS compounds such as GHRP-6. Subsequent research in swine models examined ipamorelin’s effect on GH pulse amplitude and IGF-1 concentrations, with findings published in Growth Hormone & IGF Research. The selectivity profile of ipamorelin has made it a preferred research tool when investigators wish to isolate GHS-R1a-mediated GH release from broader HPA axis perturbation.

CJC-1295 and Extended Half-Life Research

CJC-1295’s DAC modification was investigated by Jetté et al. (2005) in a study published in Endocrinology, demonstrating sustained GH and IGF-1 elevation in rats and monkeys following a single administration — an effect attributable to albumin conjugation extending the effective half-life from minutes to days in those models. This pharmacokinetic profile has made CJC-1295 a subject of interest in research models where sustained GHRH receptor stimulation is the experimental condition, rather than acute pulsatile exposure.

Mechanism of Action

The proposed mechanisms for these three secretagogues operate through complementary but distinct pathways. Sermorelin and CJC-1295 are proposed to act via GHRHR on pituitary somatotrophs: receptor binding activates Gs protein, stimulating adenylyl cyclase, elevating cAMP, activating PKA, and ultimately triggering GH gene transcription and vesicular release. Ipamorelin operates through GHS-R1a, which is coupled to Gq/11 signaling — activating phospholipase C, generating IP₃ and DAG, and mobilizing intracellular calcium to drive GH exocytosis. Researchers have studied whether co-administration of a GHRHR agonist (sermorelin or CJC-1295) with a GHS-R1a agonist (ipamorelin) produces synergistic GH release in animal models, as the two receptor systems are believed to have additive or supra-additive interactions at the level of the somatotroph. IGF-1 generation in hepatic tissue is then proposed as a downstream consequence of elevated GH signaling in these models.

Supply Format for Research

Olympia Peptides supplies sermorelin, ipamorelin, and CJC-1295/ipamorelin blend as lyophilized research-grade peptides intended for laboratory use only. Each vial is supplied with purity documentation for research qualification purposes.

• Sermorelin 10mg vial — lyophilized, for reconstitution in laboratory settings
• Ipamorelin 10mg vial — lyophilized GHS-R1a agonist for in vitro or animal model research
• CJC-1295/Ipamorelin 5mg/5mg blend vial — dual-secretagogue combination for research designs studying combined receptor pathway activation

All products are supplied for laboratory research use only and are not intended for human use. Browse the full peptides research catalog for additional compounds.

Frequently Asked Questions

What is sermorelin peptide in a research context?

Sermorelin is a synthetic 29-amino-acid GHRH analogue used in preclinical research to study growth hormone secretion dynamics, GHRH receptor signaling, and GH/IGF-1 axis regulation in animal and cell-based models.

How does ipamorelin differ from sermorelin mechanistically?

Ipamorelin acts at the GHS-R1a receptor via Gq/11 signaling, while sermorelin acts at the GHRH receptor via Gs/cAMP signaling. These distinct pathways have led researchers to study whether their combination produces additive effects on GH release in animal models.

What is the research significance of CJC-1295’s extended half-life?

In animal studies, CJC-1295’s albumin-binding DAC moiety extended its effective half-life dramatically compared to native GHRH, enabling researchers to study the physiological consequences of sustained, rather than pulsatile, GHRH receptor stimulation over multi-day periods.

Are these peptides approved for human use?

No. Olympia Peptides supplies these compounds for laboratory and research use only. They are not approved for human administration and have not been evaluated by the FDA for clinical use.

What research designs use GH secretagogue peptides?

Published research has used GHS peptides in studies of pituitary cell biology, receptor pharmacology, animal aging models, and IGF-1 axis investigations. They are tools for studying endocrine signaling, not therapeutic agents.

Can these peptides be combined in research protocols?

Some published animal studies have examined combinations of GHRH analogues with GHS-R1a agonists to investigate synergistic GH secretion. CJC-1295/ipamorelin blends are available from Olympia Peptides for researchers designing such studies in appropriate laboratory settings.

Further Reading: IGF-LR3: What the Research Shows • What Are Research Peptides? • Research Peptide Storage Guide

The above content is provided for informational and educational purposes relating to scientific research only. It does not constitute medical advice, a personal health recommendation, or a treatment protocol. Olympia Peptides products are supplied for laboratory research use only. They are not intended for human consumption, injection, or clinical use, and have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. See our full disclaimer.